Urovant launches and gets rights to Merck's Phase III vibegron
Roivant Sciences Ltd. launched Urovant Sciences, which has licensed a late-stage overactive bladder candidate from Merck & Co. Inc. as its first project.
- Specialty Pharmaceuticals
- Includes Contract
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
- Reverse Licensing
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com